Ranbaxy Board Approves Spin-off Of Drug Discovery Company
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories is moving to "de-merge" its drug discovery activities into a separate company with dedicated resources, the firm announced Oct. 18